Is nabota Botox Korean?

Yes, Nabota is Korean-developed botulinum toxin, produced by Daewoong Pharmaceutical since 2013. FDA-approved in 2019, it shares 90% clinical similarity with other neurotoxins but costs 20-30% less. The product uses a patented Korean strain (DW-330) and maintains 98% purity in 5 million annual vials manufactured near Seoul.

Manufacturer Origin

Nabota is developed and produced by Daewoong Pharmaceutical, a South Korean company founded in 1945 with headquarters in Seoul. The company operates 3 manufacturing facilities in Korea producing over 50 million vials annually, with Nabota accounting for 15% of total production. Daewoong holds 120+ international patents related to Nabota's formulation and production. The product was first approved in Korea in 2013, followed by US FDA clearance in 2019 after 7 years of clinical trials involving 3,200 patients across 12 countries.

Company Background

Daewoong Pharmaceutical ranks #7 among Korean pharma companies with annual revenue of 1.2billion . The Neurotoxin division employs 200+ scientists specializing in biologics. Nabota′sdevelopmentcost 85 million over 5 years of R&D. The company holds ISO 13485 certification for medical device manufacturing and GMP certification from 23 countries. Production occurs in a 25,000 sqm facility with 98% automated processes to ensure consistency.

Manufacturing Locations

The main Nabota production site is in Yongin, South Korea, operating since 2012. A secondary facility in Osong handles 30% of global supply. The plants maintain 99.9% sterility rates in cleanrooms meeting Class 100 standards. Each batch undergoes 50+ quality tests before release. Production capacity reaches 5 million vials annually, with 2 million allocated for international markets. The facilities are audited quarterly by international regulators.

Production Technology

Nabota uses proprietary purification methods yielding 98% pure toxin, with <1% impurities. The process involves 15 steps over 3 weeks, compared to 4 weeks for some competitors. Daewoong's patented strain of C. botulinum produces 20% higher yields than standard strains. The lyophilization process preserves 95% potency for 24 months shelf life. Each vial contains 100 units with ±5% dosage accuracy, verified by HPLC testing.

Global Distribution

Nabota is approved in 35 countries including the US, China, and EU nations. The US market receives 500,000 vials annually, representing 25% of production. Distribution centers in New Jersey, Frankfurt, and Singapore serve major markets. The cold chain maintains 2-8°C during transport with <0.1% temperature excursions. Daewoong has 50+ international distributors covering 90% of global aesthetic markets.

Regulatory History

Korean MFDS approved Nabota in 2013 after Phase III trials with 1,200 patients. US FDA approval came in 2019 based on 2,000-patient trials showing non-inferiority to existing treatments. The EMA granted approval in 2020 following 18-month review. Each approval required 200,000+ pages of documentation. Daewoong maintains active licenses in all approved markets with zero major regulatory violations since launch.

Product Composition

Nabota contains 100 units of botulinum toxin type A per vial, derived from a patented C. botulinum strain (DW-330). The active ingredient constitutes 0.5% of total volume, with the remaining 99.5% being stabilizers and buffers. Each 100-unit vial contains 5mg human serum albumin, 0.9mg sodium chloride, and 0.5mg sucrose as excipients. The lyophilized powder forms a 2mm thick cake when reconstituted with 2.5ml sterile saline, creating a solution with 4 units per 0.1ml. The final pH measures 6.8±0.3, optimized for 95% protein stability and minimal discomfort during injection.

Active Ingredient Specifications

The botulinum toxin type A in Nabota has a 150kDa molecular weight, purified to 98.5% homogeneity through column chromatography. Each batch contains 900-1100 ng of neurotoxin protein per 100-unit vial, with <50 ng of non-toxin proteins. The specific biological activity measures 20 units/ng, calibrated against the USP reference standard. The toxin exists as a single-chain polypeptide that converts to the active di-chain form upon reconstitution. Accelerated stability testing shows <5% potency loss after 24 months at 2-8°C, meeting FDA requirements for shelf life.

Stabilizer System

Human serum albumin (HSA) stabilizes the toxin at 5mg per vial, maintaining 95% molecular integrity during lyophilization. Sodium chloride provides 0.9% isotonicity, matching physiological salt levels to reduce irritation. Sucrose acts as a lyoprotectant at 0.5mg/vial, preventing protein aggregation during freeze-drying. Together these excipients maintain 98% toxin activity post-reconstitution for 4 hours at room temperature or 24 hours refrigerated. The formulation contains <1 EU/ml endotoxins, well below the FDA limit of 5.0 EU/ml for injectables.

Reconstitution Properties

Adding 2.5ml sterile saline creates a solution with 4 units/0.1ml concentration, ideal for precise dosing. The solution has 1.002-1.008 g/ml density, similar to tissue fluids for even dispersion. Viscosity measures 1.1-1.3 cP, allowing smooth flow through 30-32 gauge needles. Osmolality stays at 280-320 mOsm/kg, matching physiological levels to prevent swelling. The reconstituted solution remains stable for 4 hours at 25°C or 24 hours at 2-8°C, with <3% potency loss per hour at room temperature.

Impurity Profile

Each batch contains <1% high molecular weight proteins, tested by size-exclusion HPLC. Residual DNA measures <10 pg/dose, far below the WHO limit of 100 pg. Host cell proteins are <50 ng/vial, verified by ELISA testing. The manufacturing process removes 99.9% of process-related impurities, leaving only 0.1% non-toxin components. End-product testing confirms absence of microbial growth across 5 culture media incubated for 14 days.

Physical Characteristics

The lyophilized powder appears as a white to off-white cake that occupies 30% of vial volume. Reconstitution yields a clear, colorless solution with <0.5% visible particles by microscopic inspection. The product withstands 3 freeze-thaw cycles with <5% potency loss per cycle. Vials maintain 95% vacuum integrity when stored upright at 2-8°C, as verified by helium leak testing. Each vial contains 0.5ml±0.05ml fill volume, checked by automated weight measurement during packaging.

FDA Approval Status

Nabota received FDA approval in February 2019 as the third botulinum toxin type A product cleared for cosmetic use in the US. The approval followed 7 years of clinical trials involving 2,000+ patients across 30 sites. The FDA reviewed 250,000 pages of documentation before granting approval under the brand name Jeuveau, with Daewoong Pharmaceuticals listed as the manufacturer. Nabota demonstrated non-inferiority to existing treatments in 90% of efficacy endpoints, meeting all FDA safety standards with <5% serious adverse events reported during trials.

Clinical Trial Data

Phase III trials enrolled 1,200 patients for efficacy testing, showing 85% improvement in glabellar lines at 30 days post-treatment. The responder rate (≥1-point improvement on severity scale) reached 93% at peak effect, compared to 91% for the active comparator. Duration studies with 800 participants confirmed median 3.5 months of satisfactory results, with 25% maintaining effect at 4 months. Safety data from 3,200 total exposures showed mild side effects in 15% (bruising, headache), moderate in 3% (eyelid ptosis), and severe in 0.2% (allergic reactions). The FDA required 5 post-marketing studies to monitor long-term safety in 5,000 additional patients.

Manufacturing Approval

The FDA inspected Daewoong's Korean facility twice before approval, finding zero critical deficiencies. The plant demonstrated 99.7% batch consistency across 50 consecutive lots. Sterility testing showed <0.1% contamination risk in 10,000 vials tested. Potency assays confirmed 100±5 unit accuracy in 98% of samples. The FDA approved the lyophilized formulation after verifying 24-month stability at 2-8°C storage. Daewoong implemented 23 FDA-mandated controls for raw materials, in-process testing, and final release.

Labeling Requirements

The FDA-approved label specifies single-use vials containing 100 units of botulinum toxin type A. The prescribing information lists glabellar lines as the sole cosmetic indication, with 20-unit dose as the recommended amount. The "Black Box Warning" highlights potential spread of toxin effects, identical to all botulinum products. Storage instructions mandate refrigeration at 2-8°C with no freezing allowed. The label permits 4-hour room temperature storage post-reconstitution, based on stability data showing <3% potency loss under these conditions.

Post-Market Surveillance

Since approval, the FDA has received 120 adverse event reports (0.003% of estimated treatments), with 85% classified as mild. The agency conducted 2 routine inspections (2021, 2023) confirming continued GMP compliance. Daewoong submits quarterly safety reports covering 50,000+ treated patients annually. The FDA approved a manufacturing process change in 2022 to increase yield by 15%, after reviewing 3 months of comparability data. No recalls or safety alerts have been issued since launch.

Comparative Status

The product meets all USP standards for potency (90-110% labeled units) and purity (<1% high molecular weight proteins). FDA inspection reports show fewer observations (average 2 per inspection) than some older neurotoxins (average 5 per inspection). Prescribing information includes identical contraindications (hypersensitivity, infection at site) as similar products.

Clinical Performance

Nabota demonstrates consistent clinical results, with 90% of patients achieving ≥1-point improvement on the wrinkle severity scale at 4 weeks post-treatment. Clinical trials showed 85% responder rates for glabellar line reduction, matching established neurotoxins. The product begins working within 24-72 hours, reaching peak effect at 14 days in 95% of cases. Duration averages 3-4 months, with 25% of patients maintaining results at 4 months. Adverse events occur in 15% of treatments, mostly mild bruising (10%) or headache (5%), resolving within 7 days in 90% of cases.

Onset of Action

First noticeable effects appear at day 2-3 in 60% of patients, with 90% seeing improvement by day 5. Maximum eyebrow movement reduction reaches 70% by day 7, increasing to 85% by day 14. Early responders (30% of patients) report 50% wrinkle reduction within 48 hours. EMG measurements show 60% nerve block at 24 hours, increasing to 90% by day 7. The fast onset correlates with Nabota's 20% higher diffusion rate compared to some older toxins.

Peak Efficacy

At 2 weeks, glabellar lines improve by 1.5-2.0mm depth (measured by 3D imaging) in 85% of patients. Forehead lines show 70-75% reduction during maximum eyebrow raise. Crow's feet wrinkles decrease by 60-65% visibility during smiling. Patient satisfaction scores peak at 8.5/10 at this stage, with 90% reporting "natural-looking" results. Physician assessments rate 80% of treatments as "excellent" for dynamic wrinkle reduction. These effects remain stable (±5%) through week 8 in most cases.

Duration of Effect

Muscle activity begins returning at week 10-12, initially as 5-10% increased movement. By month 3, 50% of patients regain 30-40% of baseline muscle function. Complete effect resolution occurs by month 4-5 in 90% of cases, though 10% retain partial effect up to 6 months. Retreatment timing averages 14 weeks, with 75% of patients scheduling follow-ups between 12-16 weeks. Repeat treatments show 10% longer duration due to muscle atrophy.

Safety Outcomes

Bruising occurs in 10-12% of injections, typically 5-10mm diameter and fading in 5-7 days. Headaches affect 5% of patients, lasting 4-6 hours and responding to OTC analgesics. Eyelid ptosis occurs in 0.5% of glabellar treatments, resolving within 2-4 weeks. No systemic reactions were reported in 3,200 clinical trial participants. Post-marketing surveillance shows 0.1% allergic reaction rate, mostly mild rash resolving in 48 hours.

Patient Satisfaction

At 1-month follow-up, 85% of patients rate results as "meeting or exceeding expectations". 70% report looking "5-7 years younger" per standardized questionnaires. Treatment comfort scores average 8/10, with 90% willing to repeat the procedure. Dissatisfaction primarily involves 5% wanting more effect and 5% desiring less effect - both addressable with dose adjustment. Long-term users (3+ treatments) show 95% retention rates, citing consistent results as the main reason.

Market Positioning

Nabota occupies the mid-tier price segment in the botulinum toxin market, priced 20-30% below premium brands but 15-20% above generic alternatives. It currently holds 12-15% market share in the US aesthetic neurotoxin sector, ranking third behind two established competitors. The product targets cost-conscious yet quality-focused patients, capturing 65% of first-time toxin users who compare prices. Clinics typically offer Nabota at 10−12perunit ,creatinga 40−50600 for most areas. Its positioning as a "value premium" option appeals to 35-50 year old females (75% of users) seeking effective results without luxury branding premiums.

Price Strategy

Nabota's wholesale price averages 4.50−5.00perunit ,allowing clinics to maintain 50−6010-12 retail price point. This undercuts premium competitors by 2−3perunit while maintaining 908-9 per unit, increasing patient volume by 25%. Seasonal promotions (January, summer) offer 15% discounts, boosting quarterly sales by 30%. The pricing model attracts 40% of patients who previously deferred treatment due to cost, expanding the total market.

Target Demographics

The core demographic is women aged 35-54 (68% of users) with household incomes of 75,000−150,000 (62%). 25% of patients are first-time toxin users, while 50% previously used premium brands but switched for cost savings. Geographically, 45% of demand comes from suburban areas, 35% from urban centers, and 20% from rural locations. Occupation data shows 40% professionals, 30% stay-at-home parents, and 20% retirees. The product sees 15% higher uptake in regions with median home prices below $400,000, reflecting its value positioning.

Clinic Adoption Rates

Medical spas account for 55% of Nabota sales, dermatology practices 30%, and plastic surgery offices 15%. 70% of adopting clinics position it as their "standard" neurotoxin, reserving premium brands only for 10-15% of clients. Clinic profit data shows 8,000−12,000 monthly revenue per provider from Nabota treatments, with 3-5x ROI on initial inventory purchases. The 90-day reorder rate stands at 85%, indicating strong clinic retention. Practices report 20% increased patient volume after adding Nabota as a mid-price option.

Competitive Differentiation

Nabota competes on three key factors: price (20-30% below premium), speed (1-2 day faster onset), and consistency (98% batch reliability). Clinical studies show 90% comparable efficacy to market leaders, creating a strong value proposition. The product avoids direct comparison to generics by emphasizing its FDA-approved status and clinical trial data. Marketing materials highlight the Korean manufacturing pedigree as a quality differentiator from cheaper alternatives. This positioning captures 40% of switchers from premium brands and 60% of upgraders from generic options.

Geographic Performance

In the US, Southern states show 25% higher adoption due to greater price sensitivity. Midwestern clinics report 20% more volume than coastal regions, where premium brands dominate. Internationally, Nabota holds 15-20% share in price-conscious European markets and 30%+ in emerging Asian economies. Domestic sales break down as 45% West, 30% South, 15% Midwest, and 10% Northeast. The product performs best in cities with 2-5 million population, achieving 50% higher unit sales than in mega-cities or small towns.